Search results for " cardiovascular diseases."

showing 10 items of 79 documents

High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: …

2014

BACKGROUND AND PURPOSE: Clinical and experimental evidence suggests that endothelin-1 (Et-1) plays a role in cardiac and vascular disease. In the present study, we investigated the prognostic significance of Et-1 for cerebrovascular and cardiovascular outcome, in a 20-year follow-up. METHODS: We studied 82 originally healthy individuals, referred to our Unit of Cardiovascular Prevention, to evaluate the presence of asymptomatic carotid lesions. We subdivided these individuals into two groups, according to the plasma values of Et-1 (respectively ≤ or >2.7 pg/ml). Traditional cardiovascular risk factors were investigated, and by carotid ultrasound examination, we distinguished between normal …

Carotid Artery DiseasesMalePredictive Value of TestCarotid Intima-Media ThicknessRisk FactorsCardiovascular Diseasefollow-upProspective Studiescardiovascular events; cerebrovascular events; endothelin-1; follow-up; Adult; Aged; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Endothelin-1; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plaque Atherosclerotic; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Cardiology and Cardiovascular Medicine; Medicine (all)Prospective cohort studyEndothelin-1Medicine (all)Follow up studiesGeneral MedicineMiddle AgedPrognosiscardiovascular eventPredictive valuePlaque AtheroscleroticCardiovascular DiseasesPredictive value of testsCerebrovascular DisorderCardiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosicerebrovascular eventFollow-Up StudiePredictive Value of TestsCarotid Intima-Media ThickneInternal medicinemedicineHumansAsymptomatic DiseasesAgedAsymptomatic DiseaseCarotid Artery Diseasebusiness.industryVascular diseaseRisk FactorBiomarkermedicine.diseaseEndothelin 1Settore MED/11 - Malattie Dell'Apparato CardiovascolareProspective StudieCerebrovascular DisordersHigh plasmaAsymptomatic DiseasesbusinessBiomarkersFollow-Up Studies
researchProduct

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart

2021

Nonalcoholic fatty liver disease (NAFLD) is strongly associated to the features of metabolic syndrome which can progress to cirrhosis, liver failure and hepatocellular carcinoma. However, the most common cause of mortality in people with NAFLD is not liver-related but stems from atherosclerotic cardiovascular disease (CVD). The prevalence of NAFLD is on the rise, mainly as a consequence of its close association with two major worldwide epidemics, obesity and type 2 diabetes (T2D). The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression and CVD have not been completely elucidated. Human fetuin-A (alpha-2-Heremans Schmid glycoprotein), a glycoprotein produ…

Cirrhosisalpha-2-HS-GlycoproteinQH301-705.5030209 endocrinology & metabolismReviewType 2 diabetes030204 cardiovascular system & hematologyBioinformaticsdigestive systemCatalysisInorganic ChemistryPathogenesis03 medical and health sciences0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseNAFLDNonalcoholic fatty liver diseaseAnimalsHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologyCVD Fetuin‐A NAFLD Animals Cardiovascular Diseases Fibrosis Humans Liver Non-alcoholic Fatty Liver Disease alpha-2-HS-GlycoproteinSpectroscopybusiness.industryOrganic Chemistrynutritional and metabolic diseasesGeneral MedicineCVDmedicine.diseaseFibrosisObesitydigestive system diseasesFetuin-AComputer Science ApplicationsChemistryLiverCardiovascular DiseasesHepatocellular carcinomaMetabolic syndromebusinessInternational Journal of Molecular Sciences
researchProduct

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

2018

Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available suppleme…

ConsensusFunctional foodsClinical Decision-MakingFood supplementDisease030204 cardiovascular system & hematologyLDL03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalPlasma cholesterolRisk FactorsEnvironmental healthFood supplementsRed yeast riceMedicineAnimalsHumans030212 general & internal medicineCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Clinical Decision-Making; Consensus; Dyslipidemias; Evidence-Based Medicine; Humans; Protective Factors; Risk Factors; Diet Healthy; Dietary Supplements; Functional Food; Risk Reduction BehaviorDyslipidemiasPharmacologyLdl cholesterolHealthyEvidence-Based MedicinePrimary preventionCholesterolbusiness.industryFunctional foodFood supplementation functional foods cholesterol LDL-cholesterol cardiovascular risk primary preventionCholesterol LDLProtective FactorsCardiovascular riskDietCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; PharmacologyYoung ageCholesterolchemistryCardiovascular DiseasesDietary SupplementsLDL cholesterolPosition paperDiet HealthybusinessRisk Reduction BehaviorBiomarkers
researchProduct

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

2022

Introduction: Inclisiran is a novel posttranscriptional gene silencing therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis by RNA interference and has a potent, dose-dependent, durable effect in lowering LDL-C, and therefore is an effective drug to treat dyslipidemia, reducing the risk for acute cardiovascular (CV) events. It is safe and well-tolerated. Areas covered: This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program. Expert opinion: Data from the clinical trials in the ORION program demonstrated efficacy and safety o…

DrugSmall interfering RNAmedia_common.quotation_subjectHypercholesterolemiaPlaceboBioinformaticsLDLPCSK9RNA interferencemedicineAnimalsHumansPharmacology (medical)Gene SilencingRNA Small InterferingAdverse effectDyslipidemiasmedia_commontherapy.business.industryPCSK9General Medicinemedicine.diseaseClinical trialCardiovascular DiseasesAtherosclerosis inclisiran LDL PCSK9 RNA therapy Animals Cardiovascular Diseases Dyslipidemias Gene Silencing Humans Hypercholesterolemia Proprotein Convertase 9 RNA Small InterferingAtherosclerosiRNAProprotein Convertase 9businessinclisiranDyslipidemiaExpert Opinion on Drug Safety
researchProduct

Insight into the Evolving Role of PCSK9

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine protease plays a pivotal role in the reduction of the number of low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes, which leads to an increase in the level of cholesterol in the blood. This mechanism and the fact that gain of function (GOF) mutations in PCSK9 are responsible for causing familial hypercholesterolemia whereas loss-of-function (LOF) mutations are associated with hypocholesterolemia, prompted the invention of drugs that block PCSK9 action. The high efficiency of PCSK9 inhibitors (…

Endocrinology Diabetes and MetabolismPCSK9; cholesterol; anti-PCSK9; cardiovascular diseases; genetic; atherosclerosis; alirocumab; evolocumab; inclisiranMolecular BiologyBiochemistryMetabolites
researchProduct

Confidence-based Somatic Mutation Evaluation and Prioritization

2012

Next generation sequencing (NGS) has enabled high throughput discovery of somatic mutations. Detection depends on experimental design, lab platforms, parameters and analysis algorithms. However, NGS-based somatic mutation detection is prone to erroneous calls, with reported validation rates near 54% and congruence between algorithms less than 50%. Here, we developed an algorithm to assign a single statistic, a false discovery rate (FDR), to each somatic mutation identified by NGS. This FDR confidence value accurately discriminates true mutations from erroneous calls. Using sequencing data generated from triplicate exome profiling of C57BL/6 mice and B16-F10 melanoma cells, we used the exist…

False discovery rateSequence analysisSomatic cellQH301-705.5Low ConfidenceDNA Mutational AnalysisBiologySensitivity and SpecificityDNA sequencing03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineGermline mutationGenetic MutationGeneticsAnimalsExomeFalse Positive ReactionsGenome SequencingBiology (General)Molecular BiologyExomeBiologyMelanomaEcology Evolution Behavior and SystematicsHealth aging / healthy living Cardiovascular diseases [IGMD 5]030304 developmental biologyGenetics0303 health sciencesEcologyReceiver operating characteristicComputational BiologyReproducibility of ResultsGenomicsDNA NeoplasmSequence Analysis DNAMice Inbred C57BLComputational Theory and Mathematics030220 oncology & carcinogenesisModeling and SimulationMutationArtifactsResearch Article
researchProduct

Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study

2016

Objective  To evaluate the combined associations of diet, physical activity, moderate alcohol consumption, and smoking with body weight on risk of all cause and cause specific mortality. Design  Longitudinal study with up to 32 years of follow-up. Setting  Nurses’ Health Study (1980-2012) and Health Professionals Follow-up Study (1986-2012). Participants  74 582 women from the Nurses’ Health Study and 39 284 men from the Health Professionals Follow-up Study who were free from cardiovascular disease and cancer at baseline. Main outcome measures  Exposures included body mass index (BMI), score on the alternate healthy eating index, level of physical activity, smoking habits, and alcohol drink…

GerontologyAdultMaleStatistics as TopicDisease030204 cardiovascular system & hematologyLower riskBody Mass IndexCohort Studies03 medical and health sciences0302 clinical medicineSex FactorsBiasEnvironmental healthNeoplasmsCause of DeathDiabetes MellitusMedicineHealth Status IndicatorsHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyf body weightLife StyleCause of deathAged2. Zero hungerbusiness.industryResearchHazard ratioBody WeightAdult; Aged; Bias (Epidemiology); Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus Type 2; Female; Health Status Indicators; Health Surveys; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Prospective Studies; Sex Factors; Statistics as Topic; United States; Body Weight; Cause of Death; Life Stylelifestyle factorsGeneral MedicineMiddle AgedHealth SurveysConfidence intervalUnited States3. Good healthDiabetes Mellitus Type 2Cardiovascular DiseasesBias (Epidemiology)FemalebusinessBody mass indexType 2Cohort study
researchProduct

RISK OF CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY IN FRAIL AND PRE-FRAIL OLDER ADULTS:RESULTS FROM A META-ANALYSIS AND EXPLORATORY META-REGRESSI…

2017

Frailty is common and associated with poorer outcomes in the elderly, but its role as potential cardiovascular disease (CVD) risk factor requires clarification. We thus aimed to meta-analytically evaluate the evidence of frailty and pre-frailty as risk factors for CVD. Two reviewers selected all studies comparing data about CVD prevalence or incidence rates between frail/pre-frail vs. robust. The association between frailty status and CVD in cross-sectional studies was explored by calculating and pooling crude and adjusted odds ratios (ORs)+/- 95% confidence intervals (CIs); the data from longitudinal studies were pooled using the adjusted hazard ratios (HRs). Eighteen cohorts with a total …

GerontologyAging1303 Biochemistry030204 cardiovascular system & hematologyBiochemistry0302 clinical medicineRisk Factorscardiovascular diseasePrevalenceMedicine030212 general & internal medicineCardiovascular disease; Frailty; Meta-analysis; Aged; Frail Elderly; Humans; Prevalence; Risk Assessment; Risk Factors; Cardiovascular Diseases; Biotechnology; Biochemistry; Aging; Molecular Biology; NeurologyOXIDATIVE STRESSProspective cohort studyELDERLY-PATIENTSPOPULATIONeducation.field_of_studyFrailtyHazard ratioMENASSOCIATION16. Peace & justiceCardiovascular disease3. Good healthMIDLIFE OBESITYNeurologyCardiovascular DiseasesMeta-analysis1305 BiotechnologyRisk assessmentCardiovascular disease; Frailty; Meta-analysis; Aged; Frail Elderly; Humans; Prevalence; Risk Assessment; Risk Factors; Cardiovascular DiseasesBiotechnologymedicine.medical_specialtyWOMENS-HEALTHFrail ElderlyPopulationCardiovascular disease; Frailty; Meta-analysis; Biotechnology; Biochemistry; Aging; Molecular Biology; Neurology610 Medicine & healthfrailtyFrailty Cardiovascular disease Meta-analysisRisk AssessmentArticle03 medical and health sciences1302 AgingInternal medicine1312 Molecular BiologyHumansCORONARY-HEART-DISEASERisk factorFrailty cardiovascular disease meta-analysiseducationMolecular BiologyAgedbusiness.industryAGE FRAILTYOdds ratio10060 Epidemiology Biostatistics and Prevention Institute (EBPI)Confidence intervalmeta-analysisMeta-analysis3121 General medicine internal medicine and other clinical medicine2808 NeurologyFOLLOW-UPbusiness
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Resveratrol: preventing properties against vascular alterations and ageing.

2005

International audience; Cardiovascular diseases are the leading cause of death in developed countries where the common pathological substrate underlying this process is atherosclerosis. Several new concepts have emerged in relation to mechanisms that contribute to the regulation of the vascular diseases and associated inflammatory effects. Recently, potential antioxidants (vitamin E, polyphenols) have received much attention as potential anti-atherosclerotic agents. Among the polyphenols with health benefic properties, resveratrol, a phytoalexin of grape, seem to be a good candidate protecting the vascular walls from oxidation, inflammation, platelet aggregation, and thrombus formation. In …

MESH : Oxidative StressAgingAntioxidantPlatelet AggregationArteriosclerosismedicine.medical_treatmentResveratrolPharmacologymedicine.disease_causeMuscle Smooth Vascularchemistry.chemical_compoundMESH : VasodilationMESH : Foam CellsMESH : Platelet AggregationStilbenesMESH : Cardiovascular DiseasesMESH : Macrophageschemistry.chemical_classificationNeovascularization PathologicPhytoalexinfood and beveragesVasodilationBiochemistryCardiovascular Diseasesmedicine.symptomBiotechnologyLipoproteinsInflammationHealth PromotionMESH : LipoproteinsBiologyMESH : StilbenesMESH : ArteriosclerosismedicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyReactive oxygen speciesMechanism (biology)MacrophagesMESH : HumansMESH : Neovascularization PathologicMESH : Muscle Smooth VascularMESH : AgingOxidative StresschemistryAgeingResveratrolMESH : Health PromotionOxidative stressFood ScienceFoam Cells
researchProduct